Navigation Links
Cetero Research Names Dr. Roger Hayes President of Bioanalytical Operations
Date:1/19/2011

CARY, N.C., Jan. 19, 2011 /PRNewswire/ -- Cetero Research, the leading early-stage contract research organization (CRO), today announced the appointment of Roger N. Hayes, Ph.D., to the role of President, Bioanalytical Operations. Dr. Hayes brings more than 15 years of scientific experience and leadership in bioanalytical testing, pharmacokinetics and pharmacodynamics, as well as extensive expertise in drug metabolism, high-throughput drug discovery and drug development.

(Photo: http://photos.prnewswire.com/prnh/20110119/PH32380 )

"We are honored to have such an accomplished scientist and business leader join us. Cetero is committed to bringing innovation to drug development, and his appointment is one additional step in allowing us to accomplish that goal. Roger has in-depth experience developing bioanalytical methods using mass spectrometry, chromatography and automation, which will allow us to enhance our analytical service offerings to our clients," said Troy W. McCall, Ph.D., CEO of Cetero Research. "In addition, Roger's vast knowledge of the entire drug development process will help us develop more innovative and effective solutions to help our clients improve efficiencies in their development processes."

For the last 10 years, Dr. Hayes served as Director of Bioanalytical at Schering-Plough Research Institute, part of Merck Research Laboratories. He has also held positions with Parke-Davis Pharmaceuticals, now a division of Pfizer; Procter and Gamble; and University of Nebraska-Lincoln and spent five years as a co-administrator of a National Science Foundation mass spectrometry research facility.

"Cetero continues to look for ways to meet the evolving needs of our diverse client base," continued Dr. McCall. "Roger's long-standing relationships with leading technology and instrumentation manufacturers will allow Cetero to remain at the cutting edge of new technology and expand our collaborations with the industry's leading innovators."

Dr. Hayes commented, "I am very excited to be joining the leader in early-stage clinical research. I believe that my background, experience and leadership style will allow me to significantly contribute to the continued growth of the bioanalytical group, and certainly Cetero as a whole."

Dr. Hayes holds three degrees, including a Ph.D. in Organic Chemistry, from the University of Adelaide in his native Australia. He has also co-authored more than 85 articles in peer-reviewed journals and given more than 20 presentations at national meetings, solidifying his status as a key thought leader in the biopharmaceutical industry. Dr. Hayes is an active member of the American Society for Mass Spectrometry and Allied Topics, the Boston Society of Advanced Therapeutics and currently serves as program chair for the 14th Annual Symposium on Chemical and Pharmaceutical Structure Analysis (CPSA 2011). He will be based in Cetero's bioanalytical laboratory in Houston.

About Cetero Research

Cetero Research is the leading early-stage contract research organization (CRO). With nearly 30 years of experience from its founding companies, Cetero has conducted more than 20,000 clinical pharmacology studies – more than any other CRO. Cetero's proven track record allows the company to provide flexible and high-quality drug-development services. The company's time-tested systems produce consistent and reliable data clients can trust. Cetero's clinical research expertise consists of traditional early-stage, healthy-volunteer clinical pharmacology and bioavailability studies, as well as specialty Phase Ia/b trials in patients. Its bioanalytical services support clinical, preclinical drug and biomarker analysis for small and large molecules. For more information, visit www.cetero.com, or call 877.7CETERO.


'/>"/>
SOURCE Cetero Research
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cetero Research Launches Seminar Series on Accelerated Proof-of-Concept in Drug Development
2. Cetero Research Leads Industry in Human Allergy Models
3. WaferGen Appoints World-Renowned Clinical Genomics Cancer Researcher Dr. Arul M. Chinnaiyan to Scientific Advisory Board
4. Octapharma Targets Primary Immune Deficiency Research With Grant for The Mount Sinai Medical Center
5. Independent Clinical Research Confirms Clinical Efficacy and Cost-Effectiveness of the SurgiCount Safety-Sponge® System
6. Best Practices, LLC Research Highlights Critical Role of Medical Affairs in New Product Launch Success
7. Pacira Pharmaceuticals Presents New Data from EXPAREL Phase 3 Study at Orthopaedic Research Societys 57th Annual Meeting
8. S&P Equity Research Issues Health Care Sector Predictions for 2011
9. $1,700,000 Funding of NeoStems Very Small Embryonic-Like Stem Cells Being Developed to Treat Osteoporosis Recommended by the Department of Defense Peer Reviewed Medical Research Program
10. Solta Medical, Inc. Appoints Thomas J. Yorkey, Ph.D. to Vice President of Research & Development
11. EDC Functionality, Ease of Data Entry, and Access to Data All Factors in University of Virginia Cancer Centers Selection of the OnCore Clinical Research Management System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 8, 2016 According to ... by Product (Actual Sugars, Sugar Alcohols, Artificial Sweeteners), ... Tonicity Agents), Formulation (Oral, Topical, Parenteral) - Global ... has witnessed healthy growth during the last decade, ... of 4.3% between 2016 and 2021 to reach ...
(Date:12/8/2016)... December 8, 2016 According to a new market ... Sleep, Fetal), Therapeutic (Pain, Insulin)), End Use (Sports, Fitness, RPM), Type (Smart ... MarketsandMarkets, the global market, in terms of value, is projected to reach ... CAGR of 18.0% during the forecast period. ... ...
(Date:12/8/2016)... , Dec. 8, 2016  Hanson Research, ... of dissolution testing and diffusion testing instruments for ... acquired by Teledyne Instruments, Inc. ("Teledyne"). The move ... line of precision testing instruments, as well as ... development of new products and services. ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... Seavest Healthcare Properties ... by an affiliate of Seavest, has won a prestigious national healthcare real estate ... ambulatory care center (ACC) was named “Best New Development, MOBs and Other Outpatient ...
(Date:12/8/2016)... ... ... David J. Dykeman , Ginger Pigott , and J. Rick Taché ... Dec. 12, 2016, at the Fairmont Newport Beach in California. Greenberg Traurig is a ... & Medical Technology Group have been featured speakers at every DeviceTalks conference since 2011. ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... technologies and development solutions for drugs, biologics and consumer health products, today announced ... was set up in 2006 as a non-profit organization to unite pharmaceutical and ...
(Date:12/8/2016)... ... December 08, 2016 , ... Today’s patients are encouraged to ... mind, SIGVARIS has created a new line of anti-embolism stockings to help prevent ... the benefits of graduated compression when transitioning from recovery to early rehabilitation. , ...
(Date:12/8/2016)... ... 08, 2016 , ... The Dianne Michael Insurance Agency, an ... County, is embarking on a charity drive with the aim of generating support ... orphaned or neglected senior dogs in the Cincinnati region, and LuvFurMutts volunteers also ...
Breaking Medicine News(10 mins):